Voices
Arsela Prelaj on Advancing Safe Integration of Radiotherapy and Targeted Agents
Arsela Prelaj /LinkedIn

Arsela Prelaj on Advancing Safe Integration of Radiotherapy and Targeted Agents

Arsela Prelaj, Medical Oncologist and PhD in Bioengineering at IRCCS Foundation National Cancer Institute, shared a post on LinkedIn:

“New Publication.

Our multidisciplinary ESMO-ESTRO consensus on the safety of combining radiotherapy (RT) with EGFR, ALK and BRAF/MEK targeted inhibitors is now live in ESMO OPEN.

Thanks to all the co-authors and Evert van Aken for his lead ESMO – European Society for Medical Oncology, European Society for Radiotherapy and Oncology (ESTRO).

In this evidence-based Delphi study, we systematically reviewed available literature and reached expert consensus on 57 clinical scenarios regarding combined RT and targeted agent safety.”

Title: ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors

Authors: E.S.M. van Aken, S.M. O’Cathail, A.K. Gandhi, J. Bussink, L. Castelo-Branco, J.G. Eriksen, G. Argilés, C.T. Hiley, V. Atkinson, J. Kaźmierska, A. Calles, K. Konopa, E. Le Rhun, F. McDonald, G. Mountzios, P.M. Putora, B. Muoio, U. Ricardi, C.B. Westphalen, A. Wrona, P. Boot, G. Pentheroudakis, C. Belka, F. Lordick, C.A.M. Marijnen, D. Martins-Branco, D. De Ruysscher, J. Barriuso, B. Devnani, M.C. de Jong, A. Prelaj

Read The Full Article

Arsela Prelaj

Other articles about Radiotherapy on OncoDaily.

A Prelaj A. Calles A. Wrona A.K. Gandhi Arsela Prelaj B. Devnani B. Muoio C. Belka C.A.M. Marijnen C.B. Westphalen C.T. Hiley cancer D. De Ruysscher D. Martins Branco E. Le Rhun E.S.M. van Aken ESMO–ESTRO F. Lordick F. McDonald G Pentheroudakis G. Argilés G. Mountzios J. Barriuso J. Bussink J. Kaźmierska J.G. Eriksen K. Konopa L. Castelo-Branco M.C. de Jong OncoDaily Oncology P. Boot P.M. Putora radiotherapy S.M. O’Cathail U. Ricardi V. Atkinson